Healthy volunteers needed to test safety of new drug DF5112
NCT ID NCT07232121
First seen Nov 18, 2025 · Last updated Apr 30, 2026 · Updated 19 times
Summary
This early-stage study tests the safety of a new drug, DF5112, in 48 healthy adults aged 18 to 55. Participants receive either the drug or a placebo by injection and are monitored for about a week in a clinic, with follow-up visits over 29 days. The goal is to check for side effects and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT MALE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Scientia Clinical Research Ltd
RECRUITINGSydney, New South Wales, 2031, Australia
Contact
Conditions
Explore the condition pages connected to this study.